Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

NCT02631577 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02631577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02631577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2015
Completion date
October 7, 2020
Enrollment
38 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, follicular